Last $0.06 USD
Change Today -0.0007 / -1.25%
Volume 113.2K
ISCO On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

international stem cell corp (ISCO) Snapshot

Open
$0.06
Previous Close
$0.06
Day High
$0.06
Day Low
$0.06
52 Week High
03/5/14 - $0.26
52 Week Low
07/9/14 - $0.06
Market Cap
14.2M
Average Volume 10 Days
633.7K
EPS TTM
$-0.07
Shares Outstanding
239.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTERNATIONAL STEM CELL CORP (ISCO)

international stem cell corp (ISCO) Related Bloomberg News

View More Bloomberg News

international stem cell corp (ISCO) Related Businessweek News

No Related Businessweek News Found

international stem cell corp (ISCO) Details

International Stem Cell Corporation, a biotechnology company, focuses on the development of therapeutic and biomedical products worldwide. Its products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cells. The company develops cell types, such as neural stem cells for the treatment of Parkinson’s disease and other central nervous system disorders; liver cells to treat congenital and acquired liver diseases; islet cells for the treatment of diabetes; and three-dimensional eye structures to treat degenerative retinal diseases and corneal blindness, as well as to accelerate corneal healing. It also offers cosmetic skin care products through professional channels and distributors, as well as through a branded Website; and human cell culture products for use in pharmaceutical, academic, and government research organizations. The company’s human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines to study breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. The company offers its human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.

42 Employees
Last Reported Date: 02/6/15
Founded in 2001

international stem cell corp (ISCO) Top Compensated Officers

Co-Chairman and Chief Executive Officer
Total Annual Compensation: $246.1K
Executive Vice President of Business Developm...
Total Annual Compensation: $220.0K
Chief Scientific Officer and Director
Total Annual Compensation: $196.9K
Compensation as of Fiscal Year 2014.

international stem cell corp (ISCO) Key Developments

International Stem Cell Corporation Announces Completion of Cell Bank for Parkinson's Disease Clinical Trial

International Stem Cell Corporation announced that the company has completed manufacturing of the cell bank of clinical-grade human neural stem cells using its patented process for the recently announced phase 1/2a clinical trial in Parkinson's disease. The cell bank contains over 2.6 billion human cells, sufficient to meet the company's foreseeable clinical trial requirements. ISCO's master cell bank of human parthenogenetic neural stem cells (ISC-hpNSC) is produced in compliance with current good manufacturing practices (cGMPs) and the chemistry and manufacturing controls (CMC) discussed in the previously reported pre-IND meeting with the FDA. The cells are karyotypically normal hpNSCs and free of measurable contaminants of human or animal origin. The production of hpNSCs from undifferentiated pluripotent human parthenogenetic stem cells in the master cell bank uses qualified reagents and a standardized protocol developed by ISCO. The undifferentiated human stem cells are derived from the parthenogenetic line and were recently cleared by the FDA for use in clinical trials. Each batch of hpNSC is subjected to standardized quality control testing to ensure viability, sterility and appropriate cellular composition before clinical use. The existing master cell bank and current production scale are sufficient to supply anticipated product needs through pivotal clinical trials. The cell bank was produced at the company's GMP manufacturing facility located in Oceanside, Calif. ISC-hpNSCs are a novel therapeutic cellular product derived from the Company's proprietary human pluripotent stem cells. Neural stem cells are self-renewing multipotent cells that are precursors for the main cell types of the central nervous system. The ability of ISC-hpNSCs to differentiate into dopaminergic neurons and express brain-protecting neurotrophic factors offers a new opportunity for the treatment of Parkinson's disease. ISCO's preclinical program includes animal studies to assess the safety and tolerability of novel cell therapy as well as doses ranging efficacy to be used to design the first clinical trial in Parkinson's disease patients.

International Stem Cell to Launch Start the Phase 1/2a Clinical Study of its Cell Therapy

International Stem Cell announced that it intends to start the phase 1/2a clinical study of its cell therapy for the treatment of Parkinson's disease in Australia within the next few months. The company has completed the required preclinical studies for the phase 1/2a clinical study of the clinical product, ISC-hpNSC, for the treatment of Parkinson's disease. This TGA submission includes non-clinical studies evaluating the safety and tolerability of the clinical product, ISC-hpNSC, in different animal species, including non-human primates, along with the chemistry and manufacturing controls and a summary of the clinical study design, according to the company.

International Stem Cell Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 05:00 PM

International Stem Cell Corporation Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 05:00 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Jay Tibor Novak, Chief Financial Officer and Secretary, Ruslan Semechkine, Chief Scientific Officer and Director, Simon Craw, Executive Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISCO:US $0.06 USD -0.0007

ISCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioheart Inc $0.0089 USD -0.0001
Cytori Therapeutics Inc $1.12 USD 0.00
Nuo Therapeutics Inc $0.25 USD -0.0125
StemCells Inc $1.11 USD -0.01
Vericel Corp $3.57 USD -0.03
View Industry Companies
 

Industry Analysis

ISCO

Industry Average

Valuation ISCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERNATIONAL STEM CELL CORP, please visit www.internationalstemcell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.